Clinical Trial Update: The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the immunological and hematological effects of STA-5326 Mesylate in patients with Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• STA-5326 Mesylate (STA-5326 mesylate)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED